Glucagon-Like Peptide-1 Links Gut Microbiota to Bone and Muscle Health

Global health faces a significant challenge from degenerative musculoskeletal diseases like osteoporosis (weak bones), sarcopenia (age-related muscle loss), and osteoarthritis. Simultaneously, imbalances in the gut microbiota, known as dysbiosis, are increasingly recognized for their widespread systemic effects. While the individual impacts of gut health and musculoskeletal integrity are well-documented, the precise molecular mechanisms connecting gut microbiota dysbiosis to the onset and progression of these debilitating musculoskeletal conditions have remained largely unclear.

The review identified GLP-1 as a crucial mediator in the gut-musculoskeletal axis. They found that gut microbiota dysbiosis can significantly impair the production and release of GLP-1 from intestinal L-cells. This reduction in GLP-1 signaling was then linked to several detrimental effects on bone and muscle health. Specifically, the authors highlighted how diminished GLP-1 activity contributes to reduced bone mineral density, impaired osteoblast (bone-forming cell) function, and increased osteoclast (bone-resorbing cell) activity, leading to bone loss. Furthermore, they proposed that GLP-1 plays a vital role in maintaining muscle mass and function by influencing protein synthesis and mitigating inflammation. The central finding is that gut microbiota dysbiosis disrupts GLP-1 signaling, which in turn acts as a direct molecular link promoting the development and progression of degenerative musculoskeletal diseases.